Oncogenic cancer/testis antigens: Prime candidates for immunotherapy

Oncotarget

Volumn 6, Issue 18, 2015, Pages 15772-15787

  Gjerstorff, Morten F ^a   Andersen, Mads H ^b   Ditzel, Henrik J ^a,c  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer testis antigen; Immunotherapy; Oncogenesis

Indexed keywords

AZACITIDINE; CANCER TESTIS ANTIGEN; CANCER VACCINE; DECITABINE; MELANOMA ANTIGEN 1; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CELL SUBPOPULATION; CELL THERAPY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENOMIC INSTABILITY; HUMAN; IMMUNOREGULATION; MELANOMA; METASTASIS; NEOPLASM; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; MALE; NEOPLASMS; PROCEDURES; TESTIS;

ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS; TESTIS;

EID: 84937946677     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4694     Document Type: Review

References (119)

1. Chen YT, Hsu M, Lee P, Shin SJ, Mhawech-Fauceglia P, Odunsi K, Altorki NK, Song CJ, Jin BQ, Simpson AJ and Old LJ. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. International journal of cancer Journal international du cancer. 2009; 124:2893-2898.
2. dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, de Bruijn DR, Kater-Baats E, Ruiter DJ, Adema GJ, van Muijen GN and van Kessel AG. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer research. 2000; 60:1654-1662.
3. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, Hayashizaki Y, Jongeneel CV, Simpson AJ, Old LJ, et al. Genome-wide analysis of cancer/testis gene expression. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:20422-20427.
4. Sahin U, Tureci O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ and Pfreundschuh M. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. International journal of cancer Journal international du cancer. 1998; 78:387-389.
5. Zendman AJ, de Wit NJ, van Kraats AA, Weidle UH, Ruiter DJ and van Muijen GN. Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma. Melanoma research. 2001; 11:451-459.
6. GjerstorffMF, Johansen LE, Nielsen O, Kock K and Ditzel HJ. Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. British journal of cancer. 2006; 94:1864-1873.
7. Greve KB, Pohl M, Olsen KE, Nielsen O, Ditzel HJ and GjerstorffMF. SSX2-4 expression in early-stage non-small cell lung cancer. Tissue antigens. 2014; 83:344-349.
8. Janitz M, Fiszer D, Michalczak-Janitz K, Lukaszyk A, Fernandez N, Skorupski W and Kurpisz M. Analysis of mRNA for class I HLA on human gametogenic cells. Molecular reproduction and development. 1994; 38:231-237.
9. Fijak M and Meinhardt A. The testis in immune privilege. Immunological reviews. 2006; 213:66-81.
10. Gotter J, Brors B, Hergenhahn M and Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. The Journal of experimental medicine. 2004; 199:155-166.
11. Tsuji T, Altorki NK, Ritter G, Old LJ and Gnjatic S. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. Journal of immunology. 2009; 183:4800-4808.
12. Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, Ellebaek E, Svane IM, Schumacher TN, Thor Straten P and Hadrup SR. Dissection of T-cell antigen specificity in human melanoma. Cancer research. 2012; 72:1642-1650.
13. Wang Y, Wu XJ, Zhao AL, Yuan YH, Chen YT, Jungbluth AA, Gnjatic S, Santiago D, Ritter G, Chen WF, Old LJ and Ji JF. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer immunity. 2004; 4:11.
14. Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, Komukai S, Nakagawa S, Odani S, Fujii H and Hatakeyama K. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer chemotherapy and pharmacology. 2004; 54:95-100.
15. Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D and Speiser D. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer research. 2003; 63:5601-5606.
16. Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A and Old LJ. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:8862-8867.
17. Qian F, Gnjatic S, Jager E, Santiago D, Jungbluth A, Grande C, Schneider S, Keitz B, Driscoll D, Ritter G, Lele S, Sood A, Old LJ and Odunsi K. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer immunity. 2004; 4:12.
18. Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Kobel M, Kalloger SE, et al. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PloS one. 2008; 3:e3409.
19. Rooney MS, Shukla SA, Wu CJ, Getz G and Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160:48-61.
20. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-70.
21. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
22. Schreiber RD, Old LJ and Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331:1565-1570.
23. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254:1643-1647.
24. Park S, Lim Y, Lee D, Cho B, Bang YJ, Sung S, Kim HY, Kim DK, Lee YS, Song Y and Jeoung DI. Identification and characterization of a novel cancer/testis antigen gene CAGE-1. Biochimica et biophysica acta. 2003; 1625:173-182.
25. Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A and Old LJ. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95:6919-6923.
26. Jager D, Unkelbach M, Frei C, Bert F, Scanlan MJ, Jager E, Old LJ, Chen YT and Knuth A. Identification of tumorrestricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. Cancer immunity. 2002; 2:5.
27. De Backer O, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T and van der Bruggen P. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer research. 1999; 59:3157-3165.
28. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M and Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94:1914-1918.
29. Scanlan MJ, Gordon CM, Williamson B, Lee SY, Chen YT, Stockert E, Jungbluth A, Ritter G, Jager D, Jager E, Knuth A and Old LJ. Identification of cancer/testis genes by database mining and mRNA expression analysis. International journal of cancer Journal international du cancer. 2002; 98:485-492.
30. Yokoe T, Tanaka F, Mimori K, Inoue H, Ohmachi T, Kusunoki M and Mori M. Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis. Cancer research. 2008; 68:1074-1082.
31. Chen YT, Venditti CA, Theiler G, Stevenson BJ, Iseli C, Gure AO, Jongeneel CV, Old LJ and Simpson AJ. Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein. Cancer immunity. 2005; 5:9.
32. Chen YT, Scanlan MJ, Venditti CA, Chua R, Theiler G, Stevenson BJ, Iseli C, Gure AO, Vasicek T, Strausberg RL, Jongeneel CV, Old LJ and Simpson AJ. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:7940-7945.
33. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, Jungbluth AA, Caballero OL, Bairoch A, Kiesler E, White SL, Simpson AJ, et al. CTdatabase: a knowledgebase of high-throughput and curated data on cancer-testis antigens. Nucleic acids research. 2009; 37:D816-819.
34. Stevenson BJ, Iseli C, Panji S, Zahn-Zabal M, Hide W, Old LJ, Simpson AJ and Jongeneel CV. Rapid evolution of cancer/testis genes on the X chromosome. BMC Genomics. 2007; 8:129.
35. Zhang Q and Su B. Evolutionary origin and human-specific expansion of a cancer/testis antigen gene family. Molecular biology and evolution. 2014; 31:2365-2375.
36. Sang M, Wang L, Ding C, Zhou X, Wang B, Wang L, Lian Y and Shan B. Melanoma-associated antigen genes - an update. Cancer letters. 2011; 302:85-90.
37. Liu Y, Zhu Q and Zhu N. Recent duplication and positive selection of the GAGE gene family. Genetica. 2008; 133:31-5.
38. GjerstorffMF and Ditzel HJ. An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. Tissue antigens. 2008; 71:187-192.
39. Killen MW, Taylor TL, Stults DM, Jin W, Wang LL, Moscow JA and Pierce AJ. Configuration and rearrangement of the human GAGE gene clusters. American journal of translational research. 2011; 3:234-242.
40. GjerstorffMF and Ditzel HJ. Limited SP17 expression within tumors diminishes its therapeutic potential. Tissue antigens. 2012; 80:523-527.
41. Mamsen LS, Brochner CB, Byskov AG and Mollgard K. The migration and loss of human primordial germ stem cells from the hind gut epithelium towards the gonadal ridge. The International journal of developmental biology. 2012; 56:771-778.
42. Old LJ. Cancer is a somatic cell pregnancy. Cancer immunity. 2007; 7:19.
43. Silva WA, Jr., Gnjatic S, Ritter E, Chua R, Cohen T, Hsu M, Jungbluth AA, Altorki NK, Chen YT, Old LJ, Simpson AJ and Caballero OL. PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer immunity. 2007; 7:18.
44. Acevedo HF, Tong JY and Hartsock RJ. Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer. 1995; 76:1467-1475.
45. Greve KB, Lindgreen JN, Terp MG, Pedersen CB, Schmidt S, Mollenhauer J, Kristensen SB, Andersen RS, Relster MM, Ditzel HJ and GjerstorffMF. Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. Mol Oncol. 2015; 9:437-449.
46. D'Arcy P, Maruwge W, Wolahan B, Ma L and Brodin B. Oncogenic Functions of the Cancer-Testis Antigen SSX on the Proliferation, Survival, and Signaling Pathways of Cancer Cells. PloS one. 2014; 9:e95136.
47. GjerstorffMF, Relster MM, Greve KB, Moeller JB, Elias D, Lindgreen JN, Schmidt S, Mollenhauer J, Voldborg B, Pedersen CB, Bruckmann NH, Mollegaard NE and Ditzel HJ. SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression. Nucleic Acids Res. 2014; 42:11433-46.
48. Mills AA. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nature reviews Cancer. 2010; 10:669-682.
49. Por E, Byun HJ, Lee EJ, Lim JH, Jung SY, Park I, Kim YM, Jeoung DI and Lee H. The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1-and E2Fdependent manner. The Journal of biological chemistry. 2010; 285:14475-14485.
50. Kim Y, Park D, Kim H, Choi M, Lee H, Lee YS, Choe J, Kim YM and Jeoung D. miR-200b and cancer/testis antigen CAGE form a feedback loop to regulate the invasion and tumorigenic and angiogenic responses of a cancer cell line to microtubule-targeting drugs. The Journal of biological chemistry. 2013; 288:36502-36518.
51. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander AR, Bokemeyer C and Kroger N. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica. 2010; 95:785-793.
52. Weeraratne SD, Amani V, Neiss A, Teider N, Scott DK, Pomeroy SL and Cho YJ. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro-oncology. 2011; 13:165-175.
53. Nardiello T, Jungbluth AA, Mei A, Diliberto M, Huang X, Dabrowski A, Andrade VC, Wasserstrum R, Ely S, Niesvizky R, Pearse R, Coleman M, Jayabalan DS, Bhardwaj N, Old LJ, Chen-Kiang S, et al. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:4309-4319.
54. Bhatia N, Xiao TZ, Rosenthal KA, Siddiqui IA, Thiyagarajan S, Smart B, Meng Q, Zuleger CL, Mukhtar H, Kenney SC, Albertini MR and Jack Longley B. MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair. The Journal of investigative dermatology. 2013; 133:759-767.
55. Kasuga C, Nakahara Y, Ueda S, Hawkins C, Taylor MD, Smith CA and Rutka JT. Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. Journal of neurosurgery Pediatrics. 2008; 1:305-313.
56. Yang B, O'Herrin S, Wu J, Reagan-Shaw S, Ma Y, Nihal M and Longley BJ. Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. The Journal of investigative dermatology. 2007; 127:267-275.
57. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M and Schneider C. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:11160-11165.
58. Doyle JM, Gao J, Wang J, Yang M and Potts PR. MAGERING protein complexes comprise a family of E3 ubiquitin ligases. Molecular cell. 2010; 39:963-974.
59. Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, Peng H, Ivanov AV, Simpson AJ and Longley BJ. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer research. 2007; 67:9954-9962.
60. Marcar L, Maclaine NJ, Hupp TR and Meek DW. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer research. 2010; 70:10362-10370.
61. Cilensek ZM, Yehiely F, Kular RK and Deiss LP. A member of the GAGE family of tumor antigens is an antiapoptotic gene that confers resistance to Fas/CD95/APO-1, Interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther. 2002; 1:380-387.
62. Kular RK, Yehiely F, Kotlo KU, Cilensek ZM, Bedi R and Deiss LP. GAGE, an antiapoptotic protein binds and modulates the expression of nucleophosmin/B23 and interferon regulatory factor 1. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2009; 29:645-655.
63. Zeng Y, He Y, Yang F, Mooney SM, Getzenberg RH, Orban J and Kulkarni P. The cancer/testis antigen prostateassociated gene 4 (PAGE4) is a highly intrinsically disordered protein. The Journal of biological chemistry. 2011; 286:13985-13994.
64. Smith SK and Kipling D. The role of replicative senescence in cancer and human ageing: utility (or otherwise) of murine models. Cytogenetic and genome research. 2004; 105:455-463.
65. Peche LY, Scolz M, Ladelfa MF, Monte M and Schneider C. MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs. Cell death and differentiation. 2012; 19:926-936.
66. Kim Y, Park H, Park D, Lee YS, Choe J, Hahn JH, Lee H, Kim YM and Jeoung D. Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs. The Journal of biological chemistry. 2010; 285:25957-25968.
67. Wong PP, Yeoh CC, Ahmad AS, Chelala C, Gillett C, Speirs V, Jones JL and Hurst HC. Identification of MAGEA antigens as causal players in the development of tamoxifenresistant breast cancer. Oncogene. 2014; 33:4579-4588.
68. Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, Luo J, Getzenberg RH and Kulkarni P. Expression of cancer/testis antigens in prostate cancer is associated with disease progression. The Prostate. 2010; 70:1778-1787.
69. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, Chen YT, Bhardwaj N, Chen-Kiang S, Old LJ and Cho HJ. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasmacell proliferation. Blood. 2005; 106:167-174.
70. Zendman AJ, van Kraats AA, den Hollander AI, Weidle UH, Ruiter DJ and van Muijen GN. Characterization of XAGE-1b, a short major transcript of cancer/testisassociated gene XAGE-1, induced in melanoma metastasis. International journal of cancer Journal international du cancer. 2002; 97:195-204.
71. Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA and Cebon J. Tumor antigen expression in melanoma varies according to antigen and stage. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12:764-771.
72. Luftl M, Schuler G and Jungbluth AA. Melanoma or not? Cancer testis antigens may help. The British journal of dermatology. 2004; 151:1213-1218.
73. Yang F, Zhou X, Miao X, Zhang T, Hang X, Tie R, Liu N, Tian F, Wang F and Yuan J. MAGEC2, an epithelialmesenchymal transition inducer, is associated with breast cancer metastasis. Breast cancer research and treatment. 2014; 145:23-32.
74. Shang B, Gao A, Pan Y, Zhang G, Tu J, Zhou Y, Yang P, Cao Z, Wei Q, Ding Y, Zhang J, Zhao Y and Zhou Q. CT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis. Cell death & disease. 2014; 5:e1285.
75. Caballero OL, Cohen T, Gurung S, Chua R, Lee P, Chen YT, Jat P and Simpson AJ. Effects of CT-Xp gene knock down in melanoma cell lines. Oncotarget. 2013; 4:531-541.
76. De Craene B and Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nature reviews Cancer. 2013; 13:97-110.
77. Kim Y, Park H and Jeoung D. CAGE, a cancer/testis antigen, induces c-FLIP(L) and Snail to enhance cell motility and increase resistance to an anti-cancer drug. Biotechnology letters. 2009; 31:945-952.
78. Woods K, Pasam A, Jayachandran A, Andrews MC and Cebon J. Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. Frontiers in oncology. 2014; 4:367.
79. Bai Q, Assou S, Haouzi D, Ramirez JM, Monzo C, Becker F, Gerbal-Chaloin S, Hamamah S and De Vos J. Dissecting the first transcriptional divergence during human embryonic development. Stem cell reviews. 2012; 8:150-162.
80. GjerstorffMF, Harkness L, Kassem M, Frandsen U, Nielsen O, Lutterodt M, Mollgard K and Ditzel HJ. Distinct GAGE and MAGE-A expression during early human development indicate specific roles in lineage differentiation. Human reproduction. 2008; 23:2194-2201.
81. Lee EK, Song KA, Chae JH, Kim KM, Kim SH and Kang MS. GAGE12 mediates human gastric carcinoma growth and metastasis. Int J Cancer. 2015; 136:2284-92.
82. Keeney S, Giroux CN and Kleckner N. Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family. Cell. 1997; 88:375-384.
83. Pousette A, Leijonhufvud P, Arver S, Kvist U, Pelttari J and Hoog C. Presence of synaptonemal complex protein 1 transversal filament-like protein in human primary spermatocytes. Human reproduction. 1997; 12:2414-2417.
84. Keeney S. Spo11 and the Formation of DNA Double-Strand Breaks in Meiosis. Genome dynamics and stability. 2008; 2:81-123.
85. Erenpreisa J and Cragg MS. MOS, aneuploidy and the ploidy cycle of cancer cells. Oncogene. 2010; 29:5447-5451.
86. Ianzini F, Kosmacek EA, Nelson ES, Napoli E, Erenpreisa J, Kalejs M and Mackey MA. Activation of meiosis-specific genes is associated with depolyploidization of human tumor cells following radiation-induced mitotic catastrophe. Cancer research. 2009; 69:2296-2304.
87. Kalejs M, Ivanov A, Plakhins G, Cragg MS, Emzinsh D, Illidge TM and Erenpreisa J. Upregulation of meiosisspecific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. BMC cancer. 2006; 6:6.
88. Cappell KM, Sinnott R, Taus P, Maxfield K, Scarbrough M and Whitehurst AW. Multiple cancer testis antigens function to support tumor cell mitotic fidelity. Molecular and cellular biology. 2012; 32:4131-4140.
89. Whitehurst AW, Xie Y, Purinton SC, Cappell KM, Swanik JT, Larson B, Girard L, Schorge JO and White MA. Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer research. 2010; 70:7652-7661.
90. GjerstorffMF, Burns J and Ditzel HJ. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment. Expert opinion on biological therapy. 2010; 10:1061-1075.
91. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:5797-5802.
92. Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jager D, Panicali D, Hoffman E, Pan L, Oettgen H, Old LJ and Knuth A. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:14453-14458.
93. Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker A, Vitale L, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Science translational medicine. 2014; 6:232ra251
94. Zhu X, Asa SL and Ezzat S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:1984-1996.
95. Liu W, Cheng S, Asa SL and Ezzat S. The melanomaassociated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer research. 2008; 68:8104-8112.
96. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature medicine. 2012; 18:1254-1261.
97. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500:415-421.
98. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26:5233-5239.
99. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29:917-924.
100. Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA and Morgan RA. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. PloS one. 2014; 9:e93321.
101. Hiasa A, Nishikawa H, Hirayama M, Kitano S, Okamoto S, Chono H, Yu SS, Mineno J, Tanaka Y, Minato N, Kato I and Shiku H. Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes. Gene Ther. 2009; 16:620-628.
102. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. Journal of immunotherapy. 2013; 36:133-151.
103. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122:863-871.
104. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Science translational medicine. 2013; 5:197ra103.
105. Makin G and Hickman JA. Apoptosis and cancer chemotherapy. Cell and tissue research. 2000; 301:143-152.
106. Pennington K, Pulaski H, Pennington M and Liu JR. Too much of a good thing: suicide prevention promotes chemoresistance in ovarian carcinoma. Current cancer drug targets. 2010; 10:575-583.
107. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P and Craddock C. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010; 116:1908-1918.
108. Toor AA, Payne KK, Chung HM, Sabo RT, Hazlett AF, Kmieciak M, Sanford K, Williams DC, Clark WB, Roberts CH, McCarty JM and Manjili MH. Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigenspecific cellular immunity. British journal of haematology. 2012; 158:700-711.
109. Sigalotti L, Coral S, Fratta E, Lamaj E, Danielli R, Di Giacomo AM, Altomonte M and Maio M. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin Oncol. 2005; 32:473-478.
110. Issa JP. Decitabine. Current opinion in oncology. 2003; 15:446-451.
111. Yan M, Himoudi N, Basu BP, Wallace R, Poon E, Adams S, Hasan F, Xue SA, Wilson N, Dalgleish A, Williams O and Anderson J. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine. Cancer immunology, immunotherapy: CII. 2011; 60:1243-1255.
112. Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE and Bollard CM. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:7058-7066
113. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010; 363:711-723.
114. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Jr., Gascon P, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England journal of medicine. 2011; 364:2517-2526.
115. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32:1020-1030.
116. Ge Y, Xi H, Ju S and Zhang X. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer letters. 2013; 336:253-259.
117. Daftarian P, Song GY, Ali S, Faynsod M, Longmate J, Diamond DJ and Ellenhorn JD. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer research. 2004; 64:5407-5414.
118. Saha A and Chatterjee SK. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scandinavian journal of immunology. 2010; 71:70-82.
119. Pedersen AE, Buus S and Claesson MH. Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. Cancer letters. 2006; 235:229-238.